Summit Corporation Share Price (SUMM)
| Bid price | 0.00 | Open price | 0.00 |
|---|---|---|---|
| Ask price | 0.00 | Prev close | 4.00 |
| High price | 0.00 | Spread | 0.00% |
| Low price | 0.00 | Volume | 0 |
Register now for FREE live Summit Corporation share prices, Summit Corporation stock quotes, charts, trades and FREE Summit Corporation company fundamentals, market news and much much more. Why not upgrade to a premium service and get Summit Corporation Level 2 Data, indepth research tools and investor commentary for Summit Corporation (SUMM) and other London Stock Exchange equities.
Summit Corporation Share Price Chart
Register now for FREE Summit Corporation share price charts
Summit Corporation Share Price Information
| Name | Summit Corporation | Epic | SUMM |
|---|---|---|---|
| Activites | Carbohydrate Services accounted for 50% of fiscal 2009 revenues; Zebralish Services, 40% and Discovery Services, 10% | Reuters | SUMM.L |
| ISIN | GB00B02T3K57 | Google Finance | LON:SUMM |
| SUMM Share Price (p) | 0.00 | Prev. Share Price (p) | 4.00 |
|---|---|---|---|
| Shares in Issue (m) | 354 | Market Cap (£m) | 17 |
| PE Ratio (x) | -3.15 | Div per share (p) | 0.00 |
| Div yield (%) | 0.00 | Div cover (x) | |
| EPS (p) | -1.50 | PEG |
Register now for FREE Summit Corporation company fundamentals
Summit Corporation Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 14/06/2012 | BUY | George Elliott | RES | 150,000 |
| 05/04/2012 | BUY | Glyn Edwards | CEO | 400,000 |
| 04/08/2010 | BUY | Steven Lee | RES | 150,000 |
| 04/08/2010 | BUY | Richard Storer | RES | 100,000 |
| 05/03/2010 | BUY | Stephen Davies | RES | 50,000 |
Summit Corporation Company News
Summit Corporation PLC : Notice of AGM
Summit Corporation PLC : Notice of AGM body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Corporation plc ('Summit' or 'the Company') NOTICE OF ANNUAL GENERAL MEETING Oxford,...
Summit says SMT19969 completes Phase I trial
AIM-quoted Summit said its narrow-spectrum antibiotic SMT 19969 for the treatment of C. difficile infection has successfully completed a Phase 1 clinical trial. SMT 19969 is a small molecule from a new class of antibiotics that has high potency and selectivity for C. difficile bacteria. The...
FLASH: Summit says SMT19969 completes Phase I trial
Story provided by StockMarketWire.com
More Summit Corporation Company News >>
Register now for FREE Summit Corporation company news
Summit Corporation Share Price Discussions
Summit Corporation PLC (SUMM)
http://www.summitplc.com/ Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease...
Summer Bonanza is upon us.......... (SUMM)
OK folks it's mid March and spring is upon us. Time to start looking ahead, the mkts have had a bit of a setback, is this the healthy correction that's been spoken about for so long or is it a buying opportunity on the road to new highs? Who knows, not me for sure, if I did I'd tell ya'll...
Register now for FREE Summit Corporation share price discussions